SNSS - Sunesis Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue6692,5363,061
Cost of Revenue---
Gross Profit6692,5363,061
Operating Expenses
Research Development21,54022,88123,701
Selling General and Administrative13,54816,11518,662
Non Recurring---
Total Operating Expenses---
Operating Income or Loss-34,419-36,460-39,302
Income from Continuing Operations
Total Other Income/Expenses Net3571583,565
Earnings Before Interest and Taxes-34,062-36,302-35,737
Interest Expense1,3961,721939
Income Before Tax-35,458-38,023-36,676
Income Tax Expense---
Minority Interest---
Net Income From Continuing Ops-35,458-38,023-36,676
Non-recurring Events
Discontinued Operations---
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income-35,458-38,023-36,676
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares-35,458-38,023-36,676